News

FDA to Again Consider Drug Aimed at Women’s Sexual Dysfunction

June 4 , 2015
by: Brigid Schulte
Orginally published in Washington Post

The Food and Drug Administration said that safety concerns outweighed any benefits, and, in 2013, again rejected the drug for approval.The manufacturer, Sprout Pharmaceuticals resubmitted an application for approval in February with additional safety studies. And on Thursday, an advisory committee of the FDA will again examine the risks and rewards of the drug. Their vote could influence the final FDA decision, due in August.

 

 

Read the full article

WARNING! THE ASRM HAS NOT REVIEWED THE CONTENTS OF THE EXTERNAL WEB SITES LISTED ON THIS PAGE, NOR CAN WE ENDORSE THEM OR THE VIEWS EXPRESSED WITHIN. 

Looking for Additional Information? Visit our provider site at

www.asrm.org
Back to Top